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Background: In individuals living with HIV infection the development of tuberculosis
(TB) is associated with rapid progression from asymptomatic TB infection to active
TB disease. Sputum-based diagnostic tests for TB have low sensitivity in minimal and
subclinical TB precluding early diagnosis. The immune response to novelMycobacterium
tuberculosis in-vivo expressed and latency associated antigens may help to measure the
early stages of infection and disease progression and thereby improve early diagnosis of
active TB disease.
Methods: Serial prospectively sampled cryopreserved lymphocytes from patients of
the Swiss HIV Cohort Study developing TB disease (“cases”) and matched patients with
no TB disease (“controls”) were stimulated with 10 novel Mycobacterium tuberculosis
antigens. Cytokine concentrations were measured in cases and controls at four time
points prior to diagnosis of TB: T1-T4 with T4 being the closest time point to diagnosis.
Results: 50 samples from nine cases and nine controls were included. Median CD4 cell
count at T4 was 289/ul for the TB-group and 456/ul for the control group. Viral loads
were suppressed in both groups. At T4 Rv2431c-induced and Rv3614/15c-induced
interferon gamma-induced protein (IP)-10 responses and Rv2031c-induced and
Rv2346/Rv2347c-induced tumor necrosis factor (TNF)-α responses were significantly
higher in cases compared to controls (p < 0.004). At T3 - being up to 2 years
prior to TB diagnosis - Rv2031c-induced TNF-α was significantly higher in cases
compared to controls (p < 0.004). Area under the receiver operating characteristics
(AUROC) curves resulted in an AUC > 0.92 for all four antigen-cytokine pairs.
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Conclusion: The in vitro Mycobacterium tuberculosis-specific immune response in
HIV-infected individuals that progress toward developing TB disease is different from
those in HIV-infected individuals that do not progress to developing TB. These differences
precede the clinical diagnosis of active TB up to 2 years, paving the way for the
development of immune based diagnostics to predict TB disease at an early stage.
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BACKGROUND
Tuberculosis (TB) remains a major global health topic with
an estimated quarter of the world’s population being latently
infected with Mycobacterium tuberculosis (1, 2). In 2019, an
estimated 10 million people developed TB disease, killing 1.4
million people worldwide. Of those ∼208,000 were co-infected
with HIV (3). HIV-infected individuals are at particular risk of
rapid progression from TB infection to subclinical and active TB
disease (4, 5). Early detection, prediction of TB progression and
treatment of TB infection and disease in these high-risk groups
is therefore crucial to prevent disease progression and further
transmission (6–9).
In the recent years, the binary perception of active versus
latent TB has been replaced with the concept that TB is
a spectrum of disease. After infection by Mycobacterium
tuberculosis the pathogen may be cleared, persist, progress to
disease in a slow or rapid fashion, or cycle through subclinical
stages before developing into symptomatic TB disease (10, 11).
Understanding of these dynamics is inherently difficult because
clinical samples are typically collected only once disease has
already developed. In this regard, the Swiss HIV Cohort Study, a
systematic longitudinal study enrolling HIV-infected individuals
in Switzerland, offers a unique opportunity to monitor the
development of disease prior to the development of clinically
apparent symptoms. We hypothesized that the analysis of the
Mycobacterium tuberculosis-specific immune response during
the time preceding clinical disease may inform on kinetics and
pathophysiology involved in this process andmay help to develop
improved early diagnostic assays.
Currently, detection of TB relies almost entirely on sputum-
based diagnostic assays which are likely to have lower sensitivity
in minimal and subclinical TB disease (12). The most developed
non-sputum-based assay used in HIV-infected individuals
detects urine lipoarabinomannan but has a very limited
sensitivity of 42% in patients with symptoms which further
decreases in those with subclinical TB disease and higher CD4
counts (13). Blood-based diagnostic tests such as interferon-γ
release assays (IGRA) using the RD1-Mycobacterium tuberculosis
antigens early secretory antigen target (ESAT)-6, and culture
Abbreviations: AUROC, area under the receiver operating characteristics; BCG,
Bacille Calmette-Guérin; CFP-10, culture filtrate protein 10; CI, confidence
interval; DosR, dormancy of survival regulon; ESAT-6, early secretory antigen
target 6; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ,
interferon-gamma; IGRA, interferon-γ release assay; IL, interleukin; IP-10, INF-
γ-inducible protein 10; ROC, receiver operating characteristics; TB, tuberculosis;
TNF-α, tumor necrosis factor α; TST, Tuberculin skin test.
filtrate protein (CFP)-10 have also a limited sensitivity of ∼69%
for detection of TB disease in HIV-infected individuals [pooled
analysis from (14)]. In some studies the sensitivity of blood-
based assays is even lower, as shown in a study within the
framework of the Swiss HIV Cohort Study with 39% having a
positive T-SPOT.TB within 6 months before culture-confirmed
TB diagnosis (15).
Recent research suggest novel antigens may help to
delineate the immune response preceding clinical disease
as Mycobacterium tuberculosis changes its gene expression
during infection and preceding clinical disease (16, 17). For
example Mycobacterium tuberculosis antigens belonging to the
group of latency associated antigens from the Mycobacterium
tuberculosis dormancy of survival regulon (DosR) are of interest
in the early and latent phases of infection (18). These genes are
activated during the dormant non-replicative state and several
studies show immune responses induced by these antigens to be
more pronounced in latent TB infection compared to TB disease
[reviewed in (16)]. Other antigens including heparin-binding
haemagglutinin (HBHA) have also been used in blood tests for
TB diagnosis (19, 20). In addition, the recently described in-vivo
expressed Mycobacterium tuberculosis antigens, expressed in
patients with pulmonary TB, have been found to elicit significant
T cell responses (21). However, no study so far has been able to
longitudinally investigate the immune response to these novel
Mycobacterium tuberculosis antigens before the development of
symptomatic TB disease.
The aim of this study was therefore to compare cytokine
production after in-vitro stimulation with novel Mycobacterium
tuberculosis antigens in HIV-infected patients up to 4 years prior
to TB diagnosis. For this we used the prospectively collected
and cryopreserved lymphocytes of the biobank of the Swiss HIV
Cohort Study that allow longitudinal testing of the immune
response prior to development of TB disease.
METHODS
Study Design and Population
This case-control study was done within the framework of
the Swiss HIV Cohort study which is a large cohort study
in Switzerland which prospectively enrolls adult HIV-infected
individuals. Demographic and clinical data including CD4 count,
HIV viral load, antiretroviral treatment and screening and
treatment of opportunistic infections are routinely collected, and
blood samples for biobanking are taken at least annually (15).
The database of the Swiss HIV Cohort study was searched
for TB cases confirmed by culture or polymerase chain reaction
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FIGURE 1 | Study sampling timeline for TB and control group.
and matched controls without a suspicion of TB and a negative
IGRA. For cases annual or biennial blood samples (T1-T4), taken
prior the diagnosis of TB disease were included. For controls two
sequential annual blood samples (T3 and T4) were included, with
T4 taken as close as possible to the negative IGRA (Figure 1,
Supplementary Table 1). Matching was done for age, sex, body
mass index, CD4 cell count, and HIV viral load.
Viability of Frozen Lymphocytes, Sample
Preparation, and Stimulation
For best possible conditions using frozen isolated peripheral
blood mononuclear cells (PBMC) the following precautions
were taken to ensure test performance: (i) sample processing in
study centers according to harmonized protocol [as described
in (15)] (ii) quality control of frozen samples in the framework
of different studies [as described in (15)] and viability check of
samples before the start of the assay (minimum of 70% recovery
rate) (iii) sample selection from three study centers only (Basel,
Berne, Zurich) to assure optimal cryopreservation and shipment
and (iv) exclusion of samples that were stored before 2001.
Thawed lymphocytes (100,000 cells/condition) were
stimulated overnight for 17 h at 37◦C with the positive
controls phytohemagglutinin (Merck chemicals LTD.,
Beeston, Nottingham, UK) at a concentration of 5µg/ml
and staphylococcus enterotoxin B (Sigma Aldrich GmbH,
Schnelldorf, Germany) at a concentration of 10µg/ml, novel
Mycobacterium tuberculosis antigens (Rv0081, Rv1733c, Rv2031c,
Rv0867c, Rv2389c, Rv3407, Rv2346/47c, Rv2431c, Rv3614/15c,
and Rv3865) and a fusion protein of ESAT-6 and CFP-10 [all
recombinant proteins expressed from Escherichia coli BL21 were
produced by Kees L.M.C. Franken from the Ottenhoff lab at
Leiden University Medical Center in the Netherlands (22)] at a
concentration of 5µg/ml and left unstimulated in the presence
of CD28 and CD49d antibodies (Biolegend Inc., San Diego, Ca
92121, USA) at a concentration of 2µg/ml each. The addition
of costimulatory antibodies CD28 and CD49d has been done
according to previously published protocols (23–25). After
stimulation supernatants were stored at −20◦C until further
analysis. Experiments were done in a biosafety level 3∗ facility.
Cytokine Measurement
Granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon gamma (IFN-γ), IFN-γ -inducible protein (IP)-10,
interleukin (IL)-1RA, IL-6, and tumor necrosis factor (TNF)-α
were measured using a human cytokine / chemokine magnetic
bead panel (Milliplex MAP kit, Merck Millipore, Billerica, MA,
USA), a Magpix Luminex instrument and Xponent software
(version 4.2 Luminex Corp, Austin, Texas, USA) according to
manufacturer’s instructions. Standard curves using a 5-parameter
logistic regression were applied to calculate concentrations of
cytokines. Antigen- and mitogen-induced cytokine production
was calculated by subtraction of non-stimulated background
concentrations from sample concentrations. Measurements
below the limit of quantification were set to 0.1 pg/ml,
measurements above the limit of quantification were set to
10,000 pg/ml (calibration range: 3.2–10,000 pg/ml). A valid
positive control was defined as an uncorrected cytokine
concentration > 20 pg/ml (26). A valid negative control was
defined as uncorrected cytokine concentration < 20 pg/ml. In
cases where the nil concentration was higher than 20 pg/ml, the
positive control had to be higher than the nil concentration.
Statistical Analysis
Results from patients with invalid positive and negative control
values were excluded from analysis for the specific time point
and cytokine. If more than 25% of measurements from all
patients for any cytokine were below the limit of quantification,
the results from this cytokine were excluded from analysis.
A Mann-Whitney U-test was used to compare differences in
cytokine concentrations between the two groups at T3 and
T4. Differences were considered significant if the p-value was
< 0.004 (Bonferroni correction for multiple testing). Receiver
operating characteristics (ROC) analyses were performed using
area under the receiver operating characteristics (AUROC) where
p-values were significant and optimal cut-off values determined.
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Differences in cytokine production between time points were
calculated as absolute difference between T3 and T4 for controls
and between T1, T2, and T3 to T4 for cases. All plots and
statistical analyses were performed using R-studio software
(version 1.1.463).
Ethical Approval
The Swiss HIV Cohort Study was approved by the ethics
committees of the different study centers and written consent was
obtained from all participants.
RESULTS
Study Population
A total of 50 samples from 18 individuals were included in the
final analysis. Seven cases were male, median age was 45 (IQR
38–51) years, median CD4 cell count was 289 cells/µl, median
RNA viral load was 16 copies/ml at T4 (Table 1). The median
(range) time between TB diagnosis and T4 lymphocyte collection
was 117 (29–312) days. In the controls seven were male, median
age was 52 (IQR 41.5–56.5) years, median CD4 count was 456
cells/µl, median RNA viral load was 0 copies/ml at T4. The
median (range) time between negative IGRA and T4 lymphocyte
collection was 0 (0–420) days (Table 1). Age, sex, body mass
index, CD4 count and RNA viral load were not significantly
different between cases and controls. At T4 seven cases and eight
controls were on antiretroviral treatment.
Antigen-Induced Cytokine Concentrations
in Cases and Controls at T3 and T4
For the final analysis at T4 results from eight individuals were
included for both study groups. At T3 results from seven
individuals in the TB group and nine in the control group
were included (Supplementary Table 2). GM-CSF, IFN-γ IL-6,
IP-10, and TNF-α were detectable in most individuals in both
study groups. Measurements for IL-1RA were commonly below
the limit of quantification and therefore excluded from analysis
(Supplementary Table 3).
Comparison of Results in TB Patients and Controls at
Time Point Closest to Diagnosis (T4)
Median cytokine concentrations in response to Mycobacterium
tuberculosis antigens were generally higher in cases compared
to controls at T4. These differences were most pronounced for
IFN-γ, IP-10, and TNF-α and reached statistical significance
for Rv2031c-induced TNF-α and Rv2346/47c-induced TNF-α (p
< 0.002 for both) as well as for Rv2431c-induced IP-10 and
Rv3614/15c-induced IP-10 (p < 0.004, p < 0.002, respectively)
(Figure 2). Importantly, cytokine concentrations for the ESAT-
6/CFP-10-induced IFN-γ were not significantly different in cases
and controls at T4 (Supplementary Table 4).
Comparison of Results in TB Patients and Controls at
Time Point 3 (T3)
Median cytokine concentrations in response to Mycobacterium
tuberculosis antigens at T3 were generally higher in
TB patients compared to controls (Figure 2). These
TABLE 1 | Characteristics of study population.
Variable Tuberculosis group (T4) Control group (T4)
N = 9 N = 9
n % n %
Median age, IQR (years) 45 (38–51) - 52 (41.5–56.5) -
Males 7 77.8 7 77.8
Median body mass
index, IQR (kg/m2 )
21.7 (20.5–23.2) - 25.8 (24.1–27.7) -
White ethnicity 6 66.7 9 100
TB disease Pulmonary 4 44.4 - -
Extrapulmonary 4 44.4 - -
Pulmonary and
extrapulmonary
1 11.1 - -
Median CD4 cell count
at TB diagnosis, IQR
(cells/µl)
289 (152–422.5) - 456 (258.5–601) -
Median HIV-RNA at TB
diagnosis, IQR
(copies/ml)
16 (0–121,500) - 0 (0–10,030) -
Median time between
cell sampling at T4 and
TB diagnosis, range
(days)
117 (29–312) - 0 (0–420) -
Median time between
cell sampling at T3 and
TB diagnosis, range
(days)
440 (68–846) - 392 (0–938) -
Antiretroviral therapy at
TB diagnosis
7 77.8 8 88.9
TST* Negative 5 55.6 2 22.2
>5–9mm 0 0 0 0
10–14mm 0 0 1 11.1
>15mm 1 11.1 0 0
Not done 3 33.3 6 66.7
IGRA Negative 0 0 9 100
Positive 1 11.1 0 0
Indeterminate 0 0 0 0
Not done 8 88.8 0 0
TB diagnosis** Culture positive 3 33.3 - -
Sputum
positive
4 44.4 - -
FNP PCR
positive
1 11.1 - -
Lymphnode
biopsy positive
1 11.1 - -
*TST, tuberculin skin test.
**One TB patient had a positive IGRA with clinical suspicion of but had no
microbiological confirmation.
trends were most pronounced for GM-CSF and TNF-α
and reached significance for Rv2031c-induced TNF-
α (p < 0.004). Median cytokine concentrations for
the ESAT-6/CFP-10 -induced IFN-γ were also not
significantly different in cases and controls at T3
(Supplementary Table 4).
Area Under the Receiver Operating Characteristics
AUROC curves resulted in high AUC for the four antigen-
cytokine pairs with significant differences between cases and
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FIGURE 2 | Box-and-whisker plots depicting median and interquartile range of cytokine concentrations results with significant differences at T4 (A) and T3 (B).
TABLE 2 | Discriminatory potential of antigen-cytokine in cases and controls at T3 and T4.
Antigen Cytokine TP TB n Controls n p-value AUROC Cut-off Sensitivity (%) Specificity (%)
Rv2431c IP-10 T4 6.0 (1.2–159.8) 8 −9.2 (−6.8-
3.2)
7 <0.004 0.929 (95% CI
= 0.800–1)
2.2 0.87 1
Rv3614/15c IP-10 T4 8.6 (0.6–238.8) 8 −0.7
(−9.3-4.7)
7 <0.002 0.964 (95% CI
= 0.881–1)
5.4 0.87 1




8 < 0.002 0.953 (95%
CI= 0.862-1)
72.9 0.87 1




8 <0.002 0.937 (95% CI
= 0.824–1)
25.3 0.87 1




9 <0.004 0.921 (95% CI
= 0.76–1)
36.3 1.0 0.89
Median concentrations of cytokines (pg/ml) and ranges (in parenthesis) induced by stimulation of lymphocytes overnight and ability to discriminate between TB group and control group.
AUROC, Area under the receiver operating characteristics.
controls: Rv2431c-induced IP-10 AUC 0.929 (95% CI = 0.800–
1; T4); Rv3614/15c-induced IP-10 AUC 0.964 (95% CI =
0.881–1: T4); Rv2031c-induced TNF-α AUC 0.953 (95% CI =
0.862–1; T4) and 0.921 (95% CI = 0.76–1; T3); Rv2346/47c-
induced TNF-α AUC 0.937 (95% CI = 0.824–1; T4). Cut-
off concentrations were 2.2 pg/ml for Rv2431c-induced IP-
10, 5.4 pg/ml for Rv3614/15c-induced IP-10, 72.9 pg/ml for
Rv2031c-induced TNF-α, 25.3 pg/ml for Rv2346/47c-induced




Differences in median cytokine concentrations between T3
and T4 in the controls were variable. Differences in GM-CSF,
IFN-γ, and IP-10 concentrations were small for most stimulatory
antigens except for ESAT-6/CFP-10 and Rv1733c. Larger
differences in cytokine concentrations were observed for IL-6
and TNF-α. For IL-6 these differences were most pronounced
following the with ESAT-6/CFP-10, Rv1733c, and Rv2389c
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FIGURE 3 | Receiver operating characteristic curves of antigen-cytokine pairs with significant difference between cases and controls at (A) T4 and (B) T3.
(Supplementary Figure 1, Figure 5 show all data in normal scale
for all cytokines).
Differences inmedian cytokine concentrations varied between
T1, T2, T3, and T4 in the TB group and no clear pattern
was detected (Figure 4). Generally, changes over time were
more pronounced for IL-6 and TNF-α. Induced cytokine
concentrations varied substantially for ESAT-6/CFP-10, Rv1733c,
Rv2389c, and Rv3865 specifically for GM-CSF, IL-6, and
TNF-α. Smaller differences in concentrations were seen in
response to Rv0081, Rv0867c, Rv3407, Rv2346/47c, Rv2431c, and
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FIGURE 4 | Difference of cytokine concentrations between T1, T2, T3, and T4 for the cases (A–C).
Rv3614/15c. Interestingly, differences in cytokine concentrations
for the three in-vivo expressed antigens (Rv2346/47c, Rv2431c,
and Rv3614/15c) over time were small among all cytokines
(Figures 4, 5A–F showing all data in normal scale for
all cytokines).
DISCUSSION
HIV-infected patients are at high risk of rapid progression from
TB infection to TB disease. This study provides the first results in
a unique setting of HIV-infected individuals with confirmed TB
diagnosis in which their immune-response can be investigated
prospectively during the stages developing TB disease prior to
clinical diagnosis. The routine annual biobanking of lymphocytes
allows analysis of potential early markers for minimal and
subclinical TB disease. In the present study we show that several
antigen-cytokine combinations clearly differentiate HIV-infected
patients developing TB from those that do not develop TB up to
2 years prior to clinical diagnosis.
The three in vivo-expressed Mycobacterium tuberculosis
antigens, Rv2346/47c, Rv2431c, and Rv3614/15c and the DosR
antigen Rv2031c induced significantly higher TNF-α and IP-
10 responses in TB patients shortly before clinical diagnosis
compared to controls. Further to this our study found, that
differences between patients developing TB and controls were
already observed more than 12 months prior to diagnosis.
Significantly different concentrations of TNF-α induced by
Rv2031c were found between 1 and 2 years prior to clinical
diagnosis of TB. Thus, this antigen-cytokine pair may serve as an
early and antigen specifically induced correlate for TB infection
and/or subclinical TB disease.
The potential of novel Mycobacterium tuberculosis
antigens has mainly been studied for diagnostic purposes
[summarized in (16)] or as novel vaccine candidates
(21). So far, no study has assessed those antigens
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FIGURE 5 | (Continued)
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FIGURE 5 | (Continued)
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FIGURE 5 | Dotplot of all cytokines in normal scale comparing TB and control group for all timepoints included (A–F). Patients receiving antiretroviral treatment are
color coded in red and patients not receiving antiretroviral treatment are color coded in blue.
during development of TB disease. We included the
latency associated antigens from the Mycobacterium
tuberculosis DosR regulon which encodes for ∼50 genes
that are activated during the dormant non-replicative
stage of TB (18). The DosR encoded antigens Rv0081,
Rv1733c, and Rv2031c were used in this study based
Frontiers in Immunology | www.frontiersin.org 10 March 2021 | Volume 12 | Article 620622
Meier et al. Immune Response Against Mtb in HIV
on evidence of previous studies that these are highly
immunogenic (27–30).
Our results are in line with the few previous studies
investigating this antigen. A study in a high TB-endemic setting
with non-HIV-infected individuals described increased TNF-α
concentrations induced by Rv2031c in patients with TB infection
compared to controls (30). Important for this antigen is the role
of measuring cytokines other than IFN-γ, as two other studies
measuring IFN-γ only did not find significant differences in
patients with TB disease, TB infection and controls (28, 31).
A further study including a subgroup of four HIV-infected
individuals also did not find noteworthy responses of IFN-γ
induced by Rv2031c and two cytokines that were not measured
in our study (IL-2, IL-17) (32).
The in vivo-expressed Mycobacterium tuberculosis antigens
included in our study have not been studied in detail in
humans. Research suggests that they are associated with virulence
(Rv2346/47c, Rv2431c, Rv3614/15c, and Rv3865) (33), in
particular Rv2346/47c, Rv3614/15c, and Rv3865 are all associated
with the ESAT-6 secretion system. Since their absence in the
Bacille Calmette-Guérin (BCG) vaccine strain, some of these
antigens are of special interest in the diagnosis of previously
immunized individuals (34). Data from our own study in
children also showed the discriminatory potential of Rv2346/47c-
induced IP-10 response in a population of HIV-negative children
for TB infection and disease compared to exposed non-infected
children (25). Further to this animal data showed the added value
of Rv2346c when pooled with ESAT-6, CFP-10 and Rv3615c in a
skin test in TB infected cattle (35).
Our study highlights the importance of antigen-induced TNF-
α and IP-10 in the immune response during TB infection
and developing disease. TNF-α seems to be key in HIV-
TB coinfection with concentrations detected in this setting
(36). Similar findings were seen in a South-African study
using Quantiferon supernatants of HIV-infected individuals with
TB and controls which showed that IP-10 was significantly
different in stimulated and unstimulated samples between
the groups (37). Generally, TNF-α is key for granuloma
formation and recruitment of immune cells to the site of
infection (38). We found TNF-α concentration to be significantly
elevated in the TB group compared to the control group
for two antigens. Several studies also show the discriminatory
potential of TNF-α in diagnosing different stages of TB
(23, 24, 39). IP-10 has been investigated in several studies
(40, 41) also including HIV-infected individuals (42–45).
In the current study and in our study using the same
assays in children (25), ex vivo IP-10 responses significantly
increased diagnostic accuracy if compared to the current
standard testing.
Importantly, the current standard immunodiagnostic
test—being IFN-γ-induced by ESAT-6/CFP-10—was unable
to differentiate cases from controls at any time point. This
suggests that the use of novel antigen-cytokine pairs is clearly
needed to improve sensitivity to detect TB infection and
disease in HIV-infected individuals. Due to its exploratory
character this study included a limited set of samples. Despite
this, clear trends in cytokine production induced by novel
Mycobacterium tuberculosis antigens between cases and controls
could be observed. The study setting prevented us from
using fresh blood for the stimulation assays. To account for
cryopreservation precautions were taken to minimize impact
on assay performance. Some cytokines showed a high range of
values and considerable variation over time. In our study setting
we are unable to determine if this is true variation due to disease
progression or variability.
CONCLUSIONS
The ex vivo Mycobacterium tuberculosis-specific immune
response of HIV-infected individuals developing TB disease is
different form HIV-infected individuals without signs of TB
infection. In line with our hypothesis, antigen specific responses
were different prior to the clinical development of TB. These
differences precede the clinical diagnosis of active TB up to 2
years, paving the way for the development of immune based
diagnostics to predict early TB disease.
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